The phrase "a symptomatic trial" is correct and usable in written English.
It can be used in contexts related to medical research or clinical studies where symptoms are being evaluated or tested.
Example: "The researchers conducted a symptomatic trial to assess the effectiveness of the new treatment on patients exhibiting specific symptoms."
Alternatives: "a symptom-based trial" or "a trial focused on symptoms".
"All these symptomatic trials are 25 years too late," said Dr. Samuel Gandy, director of the Center for Cognitive Health at the Mount Sinai School of Medicine in Manhattan, explaining that plaque begins to build as much as 25 years before Alzeheimer's symptoms appear.
Finally, the proposed methodology is demonstrated by using reported statistics on the placebo arms from several recently published symptomatic trials on AD to estimate necessary parameters and then deriving the optimum sample sizes and the time of treatment switch for future DM trials on AD.
In the original 12- to 26-week symptomatic trials of tacrine in mild to moderate AD, post hoc statistical analyses using the ApoE genotype to define subgroups of patients suggested that patients with the ApoE4 genotype progressed more rapidly on placebo and conversely were more likely to respond to treatment with tacrine [ 8].
Strokes are under-reported when surgeons report their own operative outcomes, and the risk of death and non-fatal stroke in our survey (2.5%) is much lower than that in symptomatic trials with independent assessment of patients by neurologists or stroke physicians.
In the pre-symptomatic trial (Fig 6D F), prednisolone caused a significant elevation of heart mass ratios over vehicle (5.9 ± 0.6 vs. 5.4 ± 0.4, p < 0.05), indicative of cardiac hypertrophy.
In agreement with the pre-symptomatic trial above, ProSense680 live animal imaging exhibited a 20%and13%3% decrease in muscle inflammation upon VBP15 treatment at 15 and 45 mg/kg (Fig 4G).
In the adult trial, cardiac findings were consistent with the pre-symptomatic trial (Fig 6G and H).
CRH designed, performed, and managed in vitro experiments and the in vivo pre-symptomatic trial, analysed data from both trials and wrote the paper.
Although a reasonably accurate reflection of disability and response to symptomatic treatment, motor features cannot be used as a marker of disease modification if the interventional agent has a symptomatic effect, unless a modified trial design is used such as a delayed start.
This improvement in cardiac function has been shown to translate to a symptomatic benefit in a recent trial by Davies et al. (2013), which assessed seven patients with chronic heart failure with reduced LVEF receiving renal artery denervation therapy over a six-month period.
